The protein granulocyte-colony stimulating factor (G-CSF) inhibited fibrosis in a mouse model of pulmonary fibrosis, a new study shows. The data suggests this effect is driven, in part, by stem cells from the bone marrow being recruited to the lungs. The study, “G-CSF Inhibits Pulmonary…
A new molecular probe could aid in studies of pulmonary fibrosis and other fibrotic diseases, a study reports. The study, “Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity,” was published in the Journal of the…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…
The Open Source Imaging Consortium (OSIC), a nonprofit collaborative group focused on combatting lung diseases, has launched a competition aiming to create artificial intelligence (AI) programs that can help to predict lung function decline in people with pulmonary fibrosis. Called the OSIC Pulmonary Fibrosis…
The correct way to talk about lung transplantation in relation to pulmonary fibrosis is to call it a “treatment.” I learned this early in my caregiving journey through a combination of education from my mom’s medical team and a few not-so-gentle comments from strangers when, in…
IPF Cell Atlas, the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF), is now available to the public to advance research into new treatments for the condition. This comprehensive catalogue of the complexity and diversity of 35 distinct cellular populations that are abnormal in IPF patients,…
As parts of the world begin to partially open up again amid the COVID-19 pandemic, I can’t help but feel fearful and anxious. Those of us with chronic respiratory illnesses like idiopathic pulmonary fibrosis (IPF) must regularly take precautions to avoid getting sick throughout the entire year. However, the…
Algernon Pharmaceuticals has begun screening patients for its Phase 2 clinical trial investigating its repurposed compound NP-120 (ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and associated chronic cough. The study (NCT04318704) will be conducted at three sites in Australia and two in New Zealand, all…
The protective tips of chromosomes, called telomeres, are shorter in men with idiopathic pulmonary fibrosis (IPF) than age-matched peers, and these changes seem to be linked to lower blood levels of the male hormone testosterone, a study reported. Further…
Rates of hospitalization and in-hospital mortality dropped significantly for people with idiopathic pulmonary fibrosis (IPF) in the U.S. between 2006 and 2016, and hospitalizations were most common in colder months, an analyses of disease trends found. The study, “Trends and…
Get regular updates to your inbox.
